Amgen Q1 2026 (April 30): MariTide MARITIME-1 Phase 3 Ongoing, MARITIME-2 EXTENSION Initiated, Three T2D Phase 3 Studies Slated for 2026
Amgen reported Q1 2026 revenue of $8.6 billion (+6%) on April 30 alongside an obesity-pipeline update. MariTide — a peptide-antibody conjugate that activates the GLP-1 receptor and antagonizes the GIP receptor with monthly or less frequent dosing — has the Phase 3 MARITIME-1 study ongoing in adults with obesity or overweight, and Amgen has now launched the MARITIME-2 EXTENSION study to evaluate weight-loss maintenance. Three Phase 3 studies of MariTide in people with type 2 diabetes are planned to start in 2026, alongside a Phase 2b liver-fat-reduction study and the Phase 1 study of follow-on candidate AMG 513 in obesity.